Arcus Biosciences Inc (NYSE:RCUS)
$ 15.27 -0.56 (-3.54%) Market Cap: 1.40 Bil Enterprise Value: 417.63 Mil PE Ratio: 0 PB Ratio: 2.47 GF Score: 79/100

Arcus Biosciences Inc at Evercore ISI HealthCONx Conference Transcript

Dec 02, 2020 / 03:30PM GMT
Release Date Price: $27.17 (+0.70%)
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Hey, guys, thank you all for joining us. A pleasure to have the entire management team from Arcus join us today. We have a ton to talk about. But before we do, let me first turn over to Terry. Terry, what's on top of your mind, your top priorities as we head into the new year?

Terry J. Rosen
Arcus Biosciences, Inc. - Co-Founder, Chairman & CEO

Sure. Thanks, Umer. I'll spend a few minutes just telling you how we're looking at things. So 2020 was obviously a year of a lot of execution, our collaboration with Gilead, collaboration with AstraZeneca. If you look across our programs, whether it's AB928; AB680 in the adenosine space; or AB154, our anti-TIGIT antibody, largely, you could look at this year as having been one that was focused on dose-escalation studies, dose-expansion studies and the early start of randomized studies.

So we've been pushing, since the founding of the company in 2015, to really get to what 2021 will offer,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot